{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\< 1%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.78"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.81","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\< 1%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.59"},{"ciLowerLimit":"0.55","ciPctValue":"95","ciUpperLimit":"1.04","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\< 1%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.76"},{"ciLowerLimit":"0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.68","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\>= 1%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.52"},{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.67","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\>= 1%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.50"},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.31","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\>= 1%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.97"},{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\< 5%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.62"},{"ciLowerLimit":"0.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.66","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\< 5%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.52"},{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\< 5%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.84"},{"ciLowerLimit":"0.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\>= 5%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.61"},{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\>= 5%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.59"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.53","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\>= 5%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.97"},{"ciLowerLimit":"0.48","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.75","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\< 10%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.60"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.68","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\< 10%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.54"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.14","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\< 10%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.90"},{"ciLowerLimit":"0.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\>= 10%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.69"},{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\>= 10%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.54"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.32","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\>= 10%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.77"},{"ciLowerLimit":"0.37","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.34","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression not evaluable at baseline","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.71"},{"ciLowerLimit":"0.26","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.91","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression not evaluable at baseline","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.48"},{"ciLowerLimit":"0.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression not evaluable at baseline","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.68"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG000","lowerLimit":"13.01","upperLimit":"NA","value":"23.46"},{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG001","lowerLimit":"26.45","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"13.67","upperLimit":"23.20","value":"18.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"113"}],"units":"Participants"}],"title":"PD-L1 < 1% (n=117, 123, 113)"},{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG000","lowerLimit":"39.00","upperLimit":"NA","value":"85.09"},{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG001","lowerLimit":"39.06","upperLimit":"NA","value":"82.30"},{"groupId":"OG002","lowerLimit":"16.85","upperLimit":"29.08","value":"21.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"164"}],"units":"Participants"}],"title":"PD-L1 >= 1% (n= 171, 155, 164)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.06","upperLimit":"59.24","value":"35.94"},{"groupId":"OG001","lowerLimit":"32.72","upperLimit":"114.37","value":"65.94"},{"groupId":"OG002","lowerLimit":"13.70","upperLimit":"22.51","value":"18.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"202"}],"units":"Participants"}],"title":"PD-L1 < 5% (n= 208, 210, 202)"},{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG000","lowerLimit":"33.64","upperLimit":"NA","value":"64.51"},{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG001","lowerLimit":"39.06","upperLimit":"NA","value":"104.97"},{"groupId":"OG002","lowerLimit":"18.10","upperLimit":"44.16","value":"28.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"75"}],"units":"Participants"}],"title":"PD-L1 >= 5% (n= 80, 68, 75)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.46","upperLimit":"80.85","value":"36.93"},{"groupId":"OG001","lowerLimit":"34.83","upperLimit":"107.89","value":"70.74"},{"groupId":"OG002","lowerLimit":"14.98","upperLimit":"23.03","value":"18.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"232"},{"groupId":"OG002","value":"223"}],"units":"Participants"}],"title":"PD-L1 < 10% (n= 229, 232, 223)"},{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG000","lowerLimit":"31.24","upperLimit":"NA","value":"43.63"},{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG001","lowerLimit":"39.06","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"17.45","upperLimit":"46.55","value":"29.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"title":"PD-L1 >= 10% (n= 59, 46, 54)"},{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached","groupId":"OG000","lowerLimit":"11.76","upperLimit":"NA","value":"23.89"},{"comment":"Median and Upper 95% Confidence Interval were not reached","groupId":"OG001","lowerLimit":"21.39","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"8.41","upperLimit":"30.00","value":"18.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"title":"PD-L1 Indeterminate/ Not Evaluable (n= 28, 36, 38)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"314"},{"groupId":"OG002","value":"315"}],"units":"Participants"}],"description":"OS was defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab monotherapy 3 mg/kg intravenous (IV) once every 2 weeks (Q2W) until disease progression or unacceptable toxicity","id":"OG000","title":"Nivolumab"},{"description":"Nivolumab 1 mg/kg IV combined with Ipilimumab 3 mg/kg IV once every 3 weeks (Q3W) for 4 doses followed by nivolumab 3 mg/kg IV Q2W until disease progression or unacceptable toxicity","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"Ipilimumab monotherapy 3 mg/kg IV Q3W for a total of 4 doses","id":"OG002","title":"Ipilimumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with evaluable PD-L1 expression level at baseline","reportingStatus":"POSTED","timeFrame":"From randomization until death (assessed up to approximately 128 months)","title":"Overall Survival Based on PD-L1 Expression Level","type":"SECONDARY","unitOfMeasure":"months"}